Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences Inc Opened Down Today
Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on the treatment of Alzheimer’s disease, announced that it has entered into a definitive agreement with several healthcare-focused, and other institutional investors, for the purchase of 4,081,633 shares of its common stock at a purchase price of $49.00 per share for . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.